One of OXGENE’s automated liquid handling systems, among the company’s high throughout discovery and biomanufacturing platforms powered by advanced robotics. WuXi AppTec has acquired the British contract R&D services provider for $135 million, in a deal that gives the Shanghai-based biopharma its first European facility, and broadens its portfolio of technologies for designing and developing scalable cell and gene therapies. [OXGENE]
OXGENE—founded in 2011 as Oxford Genetics Ltd. and re-branded in 2019—will continue operations under its own name as a wholly-owned subsidiary of WuXi AppTec’s cell and gene therapy business unit . . .